Neoadjuvant treatment for BRCA-mutated HER2-negative breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two oral medications (HRS-1167 and famitinib) with or without an immunotherapy drug (camrelizumab) before surgery for women with a BRCA gene mutation and HER2-negative breast cancer. It aims to see if these drugs can shrink tumors before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman between 18 and 70 years old.
- You must have a BRCA1 or BRCA2 gene mutation (proven by a blood test).
- Your breast cancer must be HER2-negative and not have spread to other organs (stage I to III, not stage IV).
- You must have a tumor that can be measured on imaging (like an MRI or CT scan).
- You must be in good general health with normal blood counts, liver, and kidney function.
- You cannot have had prior treatment with certain drugs (PARP inhibitors or VEGFR-targeted oral drugs) or a history of other cancers in the last 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests a new precision therapy given before surgery for women with a specific type of HR-positive breast cancer. It aims to see if this treatment can improve outcomes.
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
This trial tests a combination of medications given before surgery (neoadjuvant therapy) for early breast cancer. It is designed for tumors with certain “DNA repair” gene mutations and aims to improve treatment results while shrinking or controlling the cancer.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.